Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$39.27
-0.8%
$33.87
$23.23
$42.29
$1.24B0.63369,571 shs183,835 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.02
-4.4%
$20.44
$13.30
$30.03
$1.19B0.89374,264 shs236,652 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$17.26
+5.7%
$22.44
$13.70
$61.07
$319.83M3.42284,228 shs1.33 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.89
+0.6%
$6.06
$2.48
$8.03
$1.27B0.132.53 million shs1.03 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+1.10%+2.06%+27.34%+34.20%+5.80%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+0.29%+1.31%+11.79%-1.97%-5.63%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-1.92%-38.52%-22.83%-27.26%-14.95%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.01%-1.88%+41.01%+75.78%+202.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$39.27
-0.8%
$33.87
$23.23
$42.29
$1.24B0.63369,571 shs183,835 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.02
-4.4%
$20.44
$13.30
$30.03
$1.19B0.89374,264 shs236,652 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$17.26
+5.7%
$22.44
$13.70
$61.07
$319.83M3.42284,228 shs1.33 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.89
+0.6%
$6.06
$2.48
$8.03
$1.27B0.132.53 million shs1.03 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+1.10%+2.06%+27.34%+34.20%+5.80%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+0.29%+1.31%+11.79%-1.97%-5.63%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-1.92%-38.52%-22.83%-27.26%-14.95%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.01%-1.88%+41.01%+75.78%+202.70%
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.96$12.51 per share3.14$7.37 per share5.33
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$8.25 per shareN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/A$15.16 per shareN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M6.27N/AN/A($0.12) per share-65.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.0437.856.52N/A5.13%97.28%13.87%11/6/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)

Latest TECX, XERS, ELVN, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.49+$0.04-$0.49N/AN/A
8/7/2025Q2 2025
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$0.98-$1.07-$0.09-$1.07N/AN/A
8/7/2025Q2 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.27
1.18
1.10
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
32.58
32.58
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/A
25.60
25.60
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.95
1.24

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
62.63%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21031.50 million30.71 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5059.24 million43.89 millionOptionable
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
12018.71 million16.99 millionN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290161.48 million154.12 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$39.27 -0.32 (-0.82%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.02 -0.93 (-4.44%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Tectonic Therapeutic stock logo

Tectonic Therapeutic NASDAQ:TECX

$17.26 +0.93 (+5.70%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$7.88 +0.05 (+0.57%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.